$106,488.42 ownership Payment -- AbbVie Inc to Dr. Scott Collins

AbbVie Inc. reports substantial ownership interest payment to neurologist Scott Collins for Rinvoq

This page provides a detailed analysis of a $106,488.42 ownership payment from AbbVie Inc to Dr. Scott Collins. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$106,488.42
Payment Typeownership
Payment NatureOwnership or Investment Interest
Pharmaceutical CompanyAbbVie Inc
PhysicianDr. Scott Collins
NPI Number1914810945
Physician SpecialtyNeurology
LocationSyracuse, NY
Date of Payment2025-03-28
Related Drug/DeviceRinvoq
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

AbbVie Inc made a $106.5K ownership payment to Scott Collins, a Neurology specialist in Syracuse, NY. The payment was associated with Rinvoq. AbbVie Inc. reported a significant ownership interest payment of $106,488.42 to Dr. Scott Collins, a neurologist. This payment, categorized as 'Ownership or Investment Interest', was made on March 28, 2025. The payment is associated with the drug Rinvoq and involves a neurologist in Syracuse, NY.

Patient Guidance: What This Payment Means for You

If you are a healthcare provider receiving investment or ownership interest from a pharmaceutical company, ensure you understand the terms and potential conflicts of interest. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership or investment interest payments can vary widely, but a payment of this magnitude to a neurologist associated with a specific drug warrants attention compared to standard consulting or speaking fees.

Regulatory Context: Sunshine Act Requirements

Physicians must disclose ownership or investment interests in pharmaceutical companies or medical device manufacturers as required by the Physician Payments Sunshine Act.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $106.5K payment for?

This was a ownership payment of $106.5K from AbbVie Inc to Scott Collins, categorized as "Ownership or Investment Interest". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Scott Collins accept pharmaceutical money?

Yes, Scott Collins received this $106.5K payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Scott Collins's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $106.5K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Neurology?

To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Scott Collins's relationship with AbbVie Inc?

The payment amount is substantial, exceeding typical per-transaction payments. This $106.5K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Neurology?

The payment type is 'Ownership or Investment Interest', indicating a financial stake rather than a service fee.

What should patients do after learning about this payment?

If you are a healthcare provider receiving investment or ownership interest from a pharmaceutical company, ensure you understand the terms and potential conflicts of interest.

What else should I know about this ownership payment?

The payment is linked to a specific drug, Rinvoq, and a specific specialty, Neurology.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.